Optimizing Multi-channel Distribution and Inventory Agility in Pharmaceutical Industry through Demand-Based Forecasting
Introduction: The pharma ecosystem is quite complex, wherein companies operate across various channels, ranging from hospital procurement networks to retail pharmacies. While this expands their marke ...
Smart Pipeline Decisions: AI-Powered Indication Prioritization for Oncology TA
Background: In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hund ...
Mapping the Future: Identifying High-value Therapy Area Strategy for Emerging Markets
Background: In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company's growth trajectory, especiall ...
The Analogue Advantage: A Smarter Way to derive the market uptake and New Product revenue Forecast
Background: Launching a new therapy in the oncology space is one of the most complex and challenging in the pharma and biotech industries. With evolving treatment landscapes, shifting market dynamics ...
From Evidence to Impact: How Thelansis Accelerated a Rare Disease Submission
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not ...
Anticipating the Next Move: AI at the Core of Competitive Intelligence
Introduction: In today's competitive pharmaceutical industry, success relies on anticipating market changes. With rapidly growing data sources, AI-powered data analytics solutions, and predictive mod ...
Next-Gen Data Access for Pharma: How Integrated Data Ecosystems Are Powering Global Pharma Decision-Making
Introduction: In today’s dynamic pharmaceutical landscape, the need for seamless data access and faster decision-making has made AI-powered, cloud-based solutions a cornerstone of innovation. As a ph ...
From Data to Drug: How AI Transformed Clinical Trial Outcomes
Introduction: Drug discovery is a complicated, time-intensive, and expensive undertaking, fraught with vast uncertainty. Even with advancements in science and technology, many drug development progra ...
FDA Grants Priority Review for Madrigal Pharma’s Non-Alcoholic Steatohepatitis (NASH) Treatment
Madrigal Pharmaceuticals, a leading clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for nonalcoholic steatohepatitis (NASH), has exciting news to share. The U.S. ...
ChemomAb’s CM-101 Receives FDA Clearance for Phase 2 trial in Adults with Systemic Sclerosis (SSc)
ChemomAb Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application to assess CM-101 in a Phase 2 trial for systemic sclerosis (SSc ...